ArticleEuropean heart journal. Case reports2026
Transcatheter tricuspid valve replacement in arrhythmogenic right ventricular cardiomyopathy after prior cardioband annuloplasty: insights from the first-in-man case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe tricuspid regurgitation (TR) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) represents a particularly challenging clinical scenario due to advanced right ventricular dysfunction, complex device interactions, and high procedural risk. Evidence regarding transcatheter tricuspid valve replacement (TTVR) in ARVC, especially following prior transcatheter annuloplasty procedures such as Cardioband, remains scarce. Case summary: We present the first in-man case report of a successful transfemoral TTVR using the EVOQUE™ system in a 69-year-old patient with ARVC, severe TR, heart failure symptoms corresponding to New York Heart Association (NYHA) class IV, prior Cardioband annuloplasty, and an implantable cardioverter-defibrillator (ICD). The patient presented with advanced right heart failure requiring intensive pre-procedural stabilization. TTVR with a 56-mm EVOQUE™ valve resulted in an immediate reduction of TR from grade V to grade 0. The post-procedural course was complicated by severe right heart failure, respiratory insufficiency requiring prolonged mechanical ventilation, ventricular arrhythmias associated with subtherapeutic amiodarone levels, and acute kidney injury requiring temporary renal replacement therapy. Following multidisciplinary intensive care management, the patient stabilized with marked clinical improvement and sustained valve function. Discussion: This case highlights the feasibility of EVOQUE™ TTVR in patients with prior annuloplasty devices and advanced ARVC. It demonstrates the substantial risk of post-procedural right heart failure and complex device interactions, emphasizing that procedural success does not preclude a complicated clinical course. Careful patient selection, procedural planning, and intensive post-procedural management are essential in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.